Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer.

ABSTRACT:

Background

Expression of programmed death-ligand 1 (PD-L1) has been reported to correlate with response to immune checkpoint inhibitors (ICIs) in various tumor types. However, there are few data on the role of PD-L1 expression as a predictive and prognostic biomarker of sensitivity to ICIs in patients with advanced biliary tract cancer (BTC).

Objectives

We evaluated the role of PD-L1 expression as a predictive and prognostic biomarker of response to ICIs in patients with advanced BTC.

Design

We retrospectively analyzed data from 83 advanced BTC patients who received ICIs as second- or third-line treatment between February 2018 and April 2021.

Methods

All patient data analysis included evaluation of PD-L1 expression by the combined positive score (CPS).

Resul

SUBMITTER: Kim H 

PROVIDER: S-EPMC9386848 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature